The 20 references in paper D. Naskhletashvili R., V. Gorbunova A., A. Bekyashev Kh., L. Demidov V., G. Kharkevich Yu., S. Banov M., I. Samoylenko V., K. Baryshnikov А., K. Orlova V., I. Utyashev А., N. Petenko N., I. Markina G., E. Moskvina A., S. Medvedev V., Д. Насхлеташвили Р., В. Горбунова А., А. Бекяшев Х., Л. Демидов В., Г. Харкевич Ю., С. Банов М., И. Самойленко В., К. Барышников А., К. Орлова В., И. Утяшев А., Н. Петенко Н., И. Маркина Г., Е. Москвина А., С. Медведев В. (2017) “ВЕМУРАФЕНИБ В ЛЕЧЕНИИ БОЛЬНЫХ МЕЛАНОМОЙ С МЕТАСТАЗАМИ В ГОЛОВНОЙ МОЗГ // VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES” / spz:neicon:ogsh:y:2016:i:4:p:30-34

1
Schouten L.J., Rutten J., Huveneers H.A. et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698–705.
(check this in PDF content)
2
Tabouret E., Chinot O., Metellus P. et al. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 2012;32(11):4655–62.
(check this in PDF content)
3
Fife K., Colman M., Stevens G. et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004;22:1293–300.
(check this in PDF content)
4
Davies M., Liu P., McIntyre S. et al. Prognostic factors for survival in melanoma patients with bran metastases. Cancer 2011;117(8):1687–96. DOI: 10.1002/cncr.25634.
(check this in PDF content)
5
Eigentler T., Figl A., Krex D. et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011;117(8):1697–703. DOI: 10.1002/cncr.25631.
(check this in PDF content)
6
Bezjak A., Adam J., Barton R. et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002;38(4):487–96.
(check this in PDF content)
7
Khuntia D., Brown P., Li J., Mehta M.P. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006;24(8):1295–304.
(check this in PDF content)
8
Tsao M.N., Lloyd N., Wong R. et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3: CD003869.
(check this in PDF content)
9
Agarwala S., Kirkwood J., Gore M. et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22(11):2101–7.
(check this in PDF content)
10
Atkins M., Sosman J., Agarwala S. et al. Temozolomide, thalidomide and whole brain radiation therapy for patients with brain metastases from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008;113(8):2139–45. DOI: 10.1002/cncr.23805.
(check this in PDF content)
11
Margolin K., Atkins B., Thompson A. et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002;128:214–8.
(check this in PDF content)
12
Mornex F., Thomas L., Mohr P. et al. A prospective randomized multicenter phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melamoma Res 2003;13(1): 97–103.
(check this in PDF content)
13
Long G.V., Margolin K.A. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. Am Soc Clin Oncol Educ Book 2013;393–8. DOI: 10.1200/EdBook_AM.2013.33.393.
(check this in PDF content)
14
Jakob J.A., Bassett R.L. Jr, Ng C.S. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118(16):4014–23. DOI: 10.1002/cncr.26724.
(check this in PDF content)
15
Kefford R., Malo M., Arance A. et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open label, single arm, phase 2, multicenter study. Paper presented at: 2013 Society for Melanoma Research Congress; November 17–20, 2013. Philadelphia, PA.
(check this in PDF content)
16
Dummer R., Goldinger S., Turtschietal C. Vemurafenib in patients with BRAF V600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. Eur J Cancer 2014;50(3):611–21. DOI: 10.1016/j.ejca.2013.11.002.
(check this in PDF content)
17
Gibney G., Marynchenko M., Ayas C. et al. Treatment patterns and outcome in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real world setting. In: 2014 ASCO Annual Meeting.
(check this in PDF content)
18
Larkin J., DelVecchio M., Ascierto P. et al. Vemurafenib in patients with BRAF V600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014;15(4):436–44. DOI: 10.1016/S1470-2045(14)70051-8.
(check this in PDF content)
19
Berghoff A.S., Preusser M. The future of targeted therapies for brain metastases. Future Oncol 2015;11(16):2315–27. DOI: 10.2217/fon.15.127
(check this in PDF content)
20
Venur V.A., Ahluwalia M.S. Targeted Therapy in Brain Metastases: Ready for Primetime? ASCO EDUCATIONAL BOOK. 2016.
(check this in PDF content)